Consequently, patients with osteosarcoma characterized by EMT often face poorer treatment outcomes, as the presence of mesenchymal markers like N-cadherin and vimentin has been associated with lower overall survival rates and higher recurrence following chemotherapy [121]. This evidence concerns the gene CDH2 and osteosarcoma.